摘要
血液透析患者最理想的血管通路是动静脉内瘘,血栓形成是导致动静脉内瘘失败最主要原因。近期临床动静脉内瘘溶栓治疗中尿激酶和组织型纤溶酶原激活剂(t-PA)的疗效引人关注。本文简要综述近期尿激酶与t-PA在动静脉内瘘血栓形成中的应用进展。
The most ideal vascular access in hemodialysis patients is arteriovenous fistula. The main reason for the abandonment of arteriovenous fistula is thrombosis. Urokinase and tissue-type plasminogen activator （t-PA） are more and more used in the treatment of arteriovenous fistula thrombosis. This review describes the research progress of urokinase and t-PA in the treatment of arteriovenous fistula thrombosis.
出处
《世界临床药物》
CAS
2015年第11期731-734,共4页
World Clinical Drug
